Research

Gynecological Cancer Clinical Trials

The following clinical trials related to gynecological cancers are available through the WPAHS. Please click on the link for more detailed information on the trial. Below each trial is the contact information at the WPAHS.

Study Title

Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer

Principal Investigator: Eileen Segreti, M.D.

Please also contact study coordinator for more information:

Mykie Bianchi, CCRC (Phone 412.578.4316)

Internal Reference: (IRB 09-043/GOG0136 Segreti)

Cervical Cancer

Study Title

A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, In Stage IVB, Recurrent or Persistent Carcinoma of the Cervix

Principal Investigator: Eileen Segreti, M.D.

Please also contact study coordinator for more information:

Mykie Bianchi, CCRC (Phone 412.578.4316)

Internal Reference: (RC 4970/GOG 240 Segreti)

Endometrial Cancer

Study Title

GOG 210-A Molecular Staging Study of Endometrial Cancer

Principal Investigator: Eileen Segreti, M.D.

Please also contact study coordinator for more information:

Mykie Bianchi, CCRC (Phone 412.578.4316)

Internal Reference: ( 11-003/GOG Segreti)

Ovarian Cancer

Study Title

A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865, IND #7921)

Principal Investigator: Eileen Segreti, M.D.

Please also contact study coordinator for more information:

Mykie Bianchi, CCRC (Phone 412.578.4316)

Internal Reference: (RC 4967/GOG 252 Segreti)

Study Title

A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

Principal Investigator: Eileen Segreti, M.D.

Please also contact study coordinator for more information:

Mykie Bianchi, CCRC (Phone 412.578.4316)

Internal Reference: (RC 4968/GOG 212 Segreti)

Study Title

NURSE-DELIVERED WRITE SYMPTOMS© vs. SELF-DIRECTED WRITE SYMPTOMS© vs. CARE AS USUAL FOR OPTIMAL SYMPTOM MANAGEMENT FOR WOMEN WITH RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

Principal Investigator: Eileen Segreti, M.D.

Please also contact study coordinator for more information:

Mykie Bianchi, CCRC (Phone 412.578.4316)

Internal Reference: (IRB 09-042/GOG 259 Segreti)

Study Title

GOG-262: A Randomized Phase III Trial of Every 3 Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumib (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

Principal Investigator: Eileen Segreti, M.D.

Please also contact study coordinator for more information:

Mykie Bianchi, CCRC (Phone 412.578.4316)

Internal Reference: ( 5235/GOG Segreti)

Uterine Cancer

Study Title

A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus

Principal Investigator: Eileen Segreti, M.D.

Please also contact study coordinator for more information:

Mykie Bianchi, CCRC (Phone 412.578.4316)

Internal Reference: (RC 4969/GOG 261 Segreti)